Eli Lilly and Company $LLY Shares Acquired by Apollon Wealth Management LLC

Apollon Wealth Management LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 52.6% during the first quarter, Holdings Channel.com reports. The firm owned 66,192 shares of the company’s stock after purchasing an additional 22,815 shares during the period. Eli Lilly and Company makes up 1.0% of Apollon Wealth Management LLC’s holdings, making the stock its 14th biggest holding. Apollon Wealth Management LLC’s holdings in Eli Lilly and Company were worth $60,881,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of LLY. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares during the last quarter. State Street Corp boosted its position in shares of Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after purchasing an additional 635,358 shares during the period. Capital Research Global Investors increased its holdings in Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. Morgan Stanley increased its holdings in Eli Lilly and Company by 2.7% in the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after purchasing an additional 407,166 shares during the last quarter. Finally, Capital World Investors raised its position in Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after purchasing an additional 61,851 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA selected Eli Lilly for its new PreCheck pilot program, which is designed to speed review of new U.S. manufacturing facilities. That matters because Lilly is spending $27 billion to build four plants, so faster approvals could support capacity expansion and future drug supply. Article Title
• Positive Sentiment: Lilly’s Jaypirca received a positive opinion from Europe’s CHMP for chronic lymphocytic leukemia, improving the odds of broader European approval and potentially expanding the drug’s commercial opportunity. Article Title
• Positive Sentiment: The stock hit a new all-time high and 52-week high as investors reacted to recent pipeline progress, including positive Jaypirca data and expanded Medicare access for Zepbound and other obesity treatments, which boosts the outlook for Lilly’s growth franchises. Article Title

Eli Lilly and Company Trading Up 1.5%

LLY opened at $1,226.22 on Tuesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,238.00. The stock has a market capitalization of $1.15 trillion, a price-to-earnings ratio of 43.56, a PEG ratio of 1.32 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The business has a fifty day moving average price of $1,042.73 and a 200 day moving average price of $1,022.85.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LLY. HSBC cut Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their price target for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a report on Friday, May 22nd. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Weiss Ratings lowered shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, May 19th. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,235.07.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.